Palatin Technologies Announces First Patient Dosed in Second Phase I Clinical Trial of Obesity Compound from Research Collaboration

Palatin Technologies, Inc. PTN today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced. AZD2820 is a clinical candidate selected by AstraZeneca from a collaborative research program with Palatin Technologies. The phase I single center study, conducted by AstraZeneca, is expected to enroll 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m squared, in a randomized, single-blind, placebo-controlled, trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820.